Charles River Laboratories International (STU:RV6) Piotroski F-Score: 4 (As of Jun. 30, 2026) — 20% Below Median


STU:RV6 Charles River Laboratories International Inc STU:RV6
68 GF Score
Price €195.85
GF Value €169.03
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Charles River Laboratories International Piotroski F-Score?

Charles River Laboratories International STU:RV6 +3.90% 68 Piotroski F-Score is 4 as of Jun. 30, 2026, which is 20% below its 10-year median of 5.00. GuruFocus rates STU:RV6 with a GF Score™ of 68/100 and a GF Value™ of €169.03 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 210 Medical Diagnostics & Research companies, Charles River Laboratories International ranks worse than 51.43% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Charles River Laboratories International has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Charles River Laboratories International's Piotroski F-Score or its related term are showing as below:

STU:RV6' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 4

During the past 13 years, the highest Piotroski F-Score of Charles River Laboratories International was 7. The lowest was 3. And the median was 5.

Charles River Laboratories International  (STU:RV6) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Charles River Laboratories International Piotroski F-Score Related Terms


Charles River Laboratories International Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Charles River Laboratories International's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Charles River Laboratories International Piotroski F-Score Chart

Charles River Laboratories International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 6.00 4.00 5.00

Charles River Laboratories International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 4.00 5.00 4.00

STU:RV6 vs RVTY, QGEN, ICLR: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Charles River Laboratories International's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Charles River Laboratories International Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Charles River Laboratories International's Piotroski F-Score falls into.


STU:RV6
68GF Score
Charles River Laboratories International Inc STU:RV6
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 45.367 + 46.368 + -236.178 + -12.839 = €-157 Mil.
Cash Flow from Operations was 177.391 + 182.18 + 125.982 + 35.532 = €521 Mil.
Revenue was 894.861 + 856.134 + 849.07 + 861.393 = €3,461 Mil.
Gross Profit was 309.577 + 288.651 + 264.47 + 254.884 = €1,118 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(7013.689 + 6554.993 + 6401.768 + 6093.65 + 6686.716) / 5 = €6550.1632 Mil.
Total Assets at the begining of this year (Mar25) was €7,014 Mil.
Long-Term Debt & Capital Lease Obligation was €2,644 Mil.
Total Current Assets was €1,288 Mil.
Total Current Liabilities was €946 Mil.
Net Income was 83.599 + 61.88 + -205.993 + 23.559 = €-37 Mil.

Revenue was 953.263 + 909.796 + 957.434 + 910.355 = €3,731 Mil.
Gross Profit was 328.599 + 314.468 + 271.453 + 293.902 = €1,208 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(7500.56 + 7383.955 + 7211.462 + 7189.569 + 7013.689) / 5 = €7259.847 Mil.
Total Assets at the begining of last year (Mar24) was €7,501 Mil.
Long-Term Debt & Capital Lease Obligation was €2,762 Mil.
Total Current Assets was €1,393 Mil.
Total Current Liabilities was €972 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Charles River Laboratories International's current Net Income (TTM) was -157. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Charles River Laboratories International's current Cash Flow from Operations (TTM) was 521. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=-157.282/7013.689
=-0.022425

ROA (Last Year)=Net Income/Total Assets (Mar24)
=-36.955/7500.56
=-0.00492697

Charles River Laboratories International's return on assets of this year was -0.022425. Charles River Laboratories International's return on assets of last year was -0.00492697. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Charles River Laboratories International's current Net Income (TTM) was -157. Charles River Laboratories International's current Cash Flow from Operations (TTM) was 521. ==> 521 > -157 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=2643.653/6550.1632
=0.40360109

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=2761.925/7259.847
=0.38043846

Charles River Laboratories International's gearing of this year was 0.40360109. Charles River Laboratories International's gearing of last year was 0.38043846. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=1287.817/946.054
=1.36125105

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=1393.381/972.226
=1.43318632

Charles River Laboratories International's current ratio of this year was 1.36125105. Charles River Laboratories International's current ratio of last year was 1.43318632. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Charles River Laboratories International's number of shares in issue this year was 48.951. Charles River Laboratories International's number of shares in issue last year was 50.853. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1117.582/3461.458
=0.32286453

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1208.422/3730.848
=0.32390009

Charles River Laboratories International's gross margin of this year was 0.32286453. Charles River Laboratories International's gross margin of last year was 0.32390009. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=3461.458/7013.689
=0.49352887

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=3730.848/7500.56
=0.49740926

Charles River Laboratories International's asset turnover of this year was 0.49352887. Charles River Laboratories International's asset turnover of last year was 0.49740926. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+0+1+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Charles River Laboratories International has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Charles River Laboratories International (STU:RV6) has a Piotroski F-Score of 4 as of Jun. 30, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Charles River Laboratories International and its competitors. This is 20% below median its historical median of 5.00. Over the past decade, Charles River Laboratories International's Piotroski F-Score has ranged from 3.00 to 7.00. According to the industry distribution chart, Charles River Laboratories International ranks #108 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 51.4%.
Is Charles River Laboratories International's Piotroski F-Score too high?
Charles River Laboratories International's current Piotroski F-Score of 4 is 20% below median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Charles River Laboratories International's value of 4 is 20% below this industry median. Based on the distribution chart, Charles River Laboratories International ranks #108 out of 210 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Charles River Laboratories International has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Charles River Laboratories International's Piotroski F-Score compare to RVTY and QGEN?
According to the Medical Diagnostics & Research industry distribution chart, Charles River Laboratories International ranks #108 out of 210 companies for Piotroski F-Score. This places Charles River Laboratories International in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Charles River Laboratories International's value of 4 is 20% below this benchmark. Historically, Charles River Laboratories International's own Piotroski F-Score has ranged from 3.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Charles River Laboratories International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Charles River Laboratories International's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Charles River Laboratories International and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Charles River Laboratories International's current Piotroski F-Score is 4, which is 20% below median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Charles River Laboratories International stock overvalued right now?
Based on GuruFocus' analysis, Charles River Laboratories International (STU:RV6) is currently considered Modestly Overvalued. The stock's GF Value™ is €169.03, compared to a current price of €195.85 — trading 15.9% above its estimated fair value. The current Piotroski F-Score is 4, which is 20% below median its 10-year median of 5.00 and 20% below the Medical Diagnostics & Research industry median of 5.00. Charles River Laboratories International's overall GF Score™ is 68/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Charles River Laboratories International (STU:RV6), the current Piotroski F-Score is 4 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Charles River Laboratories International (STU:RV6) Overvalued in 2026?

Based on GuruFocus' analysis, Charles River Laboratories International stock appears to be overvalued. The current stock price of €195.85 is trading 15.9% above its estimated GF Value™ of €169.03. GuruFocus considers Charles River Laboratories International to be Modestly Overvalued.

Key valuation signals for STU:RV6:

  • Piotroski F-Score: 4 (20% below median its 10-year median of 5.00)
  • GF Value™: €169.03 vs. price of €195.85 (15.9% above fair value)
  • GF Score™: 68/100 with 7 warning signs
  • Industry Position: 20% below the Medical Diagnostics & Research median (#108 of 210)

No single metric tells the full story. See the STU:RV6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Charles River Laboratories International Business Description

Other Exchanges CRL:USARV6:Germany
Address 251 Ballardvale Street, Wilmington, MA, USA, 01887
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
68GF Score

Get the complete analysis for STU:RV6

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€195.85
Price
€169.03
GF Value